November 30, 2018
Astellas Pharma said on November 29 that the US FDA has approved its FLT3 inhibitor Xospata (gilteritinib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an FTL3 mutation as detected by an FDA-approved...read more